Compare Ascendis Pharma A/S (ASND) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs DigitalOcean Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while DigitalOcean Holdings Inc trades at $128.89 (market cap $13.62B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, DigitalOcean Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ASND | DOCN | |
|---|---|---|
Market Cap | $17.74B | $13.62B |
Sector | Health | Technology |
52-Week High | $277.18 | $181.29 |
52-Week Low | $163.32 | $25.74 |
Enterprise Value | $18.11B | $14.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
DigitalOcean (DOCN) trades at $130.49, down 7.38% over the past 24 hours, amid a bearish technical signal. The company reported strong Q1 2026 earnings of $0.44 per share, beating expectations, and anticipates record Q2 2026 results with remaining performance obligations exceeding $800 million. Revenue grew to $901.43 million in 2025, with a net income margin of 24.97%, though valuation ratios remain elevated with a P/E of 57.23. Analyst consensus is bullish with a $174.80 price target.
Outlook remains positive due to accelerating AI-driven cloud demand and strong execution, but risks include high valuation multiples, negative shareholder equity, and competitive pressure from hyperscalers. The stock offers growth potential if AI adoption continues, yet investors should monitor debt levels and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
